BLU 285

Drug Profile

BLU 285

Alternative Names: BLU-285

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Skin disorder therapies; Small molecules
  • Mechanism of Action Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic mastocytosis; Gastrointestinal stromal tumours
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal stromal tumours; Solid tumours; Systemic mastocytosis

Most Recent Events

  • 04 Dec 2016 Proof-of-concept data from phase I trial in Systemic mastocytosis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH Hem-2016)
  • 30 Nov 2016 Proof-of-Concept safety and efficacy data from a phase I trial in Gastrointestinal stromal tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 01 Oct 2016 BLU 285 receives Fast Track designation for Gastrointestinal stromal tumours (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, patients with PDGFRa D842V mutation regardless of prior therapy) in USA (PO,Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top